#tivicay

[pozmagazine]

Antiretrovirals Not Likely the Cause of Developmental Problems in HIV-Exposed Kids

The excess diagnosis of developmental delays among HIV-negative children born to mothers with HIV may not be exposure to antiretrovirals (ARVs) during gestation but rather the virus itself as well as the mother’s smoking or substance use during pregnancy, aidsmap reports.

Meanwhile, a recent review of scientific literature found that some ARVs are associated with preterm birth and low birth weight. Additionally, recent research indicated that Tivicay (dolutegravir), when taken during conception or the first trimester of pregnancy, was associated with birth defects.

[pozmagazine]

ViiV Seeks FDA Approval for Two-Drug HIV Treatment

ViiV Healthcare has applied to the Food and Drug Administration (FDA) for approval of the two-antiretroviral single-tablet regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) for the treatment of HIV.

The application is based on the results of the GEMINI 1 and 2 studies, which included more than 1,400 people with HIV who had viral loads up to 500,000 before starting treatment. Forty-eight-week results from the studies were presented at the International AIDS Conference in Amsterdam (AIDS 2018). By that decisive point in the studies, the two-drug combo was as effective as a three-drug regimen of Tivicay plus Truvada (tenofovir disoproxil fumarate/emtricitabine).

[pozmagazine]

Tivicay May Cause Birth Defects if Taken During First Trimester

The Food and Drug Administration (FDA) has issued a warning to women living with HIV that the antiretroviral Tivicay (dolutegravir) may cause birth defects if taken during conception or the first trimester of pregnancy, Medscape reports.

[pozmagazine]

FDA Approves Juluca, the First Two-Drug HIV Regimen

For the first time, the U.S. Food and Drug Administration (FDA) has approved an HIV treatment regimen that contains only two antiretrovirals (ARVs), instead of the standard three or more drugs. Juluca (dolutegravir/rilpivirine), a combination of drugs from ViiV Healthcare and Janssen, is approved as a new option for people with HIV who have been virally suppressed on their current ARV regimen for at least six months.

[siglerprescriptiondrugcards]

Dolutegravir

Brand Name: Tivicay

Common Dosage Forms:

Tablets: 10 mg, 25 mg, and 50 mg.

FDA Indications/Dosages:

In combination with other antiretroviral agents for the treatment of HIV-1 infections in adults and pediatric patients weighing at least 40 kg: 50 mg once daily.

In combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing between 30-40 kg: 35 mg once daily.

In combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least 6 months: 50 mg once daily.

In patients who are coadministered with certain UGTIA or CYP3A4 inducers or who are INSTI resistant: 50 mg given twice daily.

Monitor: LFT, CD4+ cell count.

Pharmacology/Pharmacokinetics: Dolutegravir inhibits the strand transfer activity of HIV-1 integrase which prevents the integration of HIV-1 DNA into host genomic DNA. This inhibition blocks the formation of the HIV-1 provirus and propagation of the viral infection. Resistance to integrase strand transfer inhibitors (INSTI) is possible and should be considered in treatment failures. After oral dosing, peak plasma levels are reached in 2-3 hours and steady state is reached in 5 days. Terminal half-life is approximately 14 hours. Metabolism is primarily via UGTA1A1 with 53% of an oral dose being excreted unchanged in the feces.

Drug Interactions: Carbamazepine, oxcarbazepine, phenytoin, phenobarbital, rifampin, and St. John’s Wort will decrease concentration of dolutegravir. Coadministration with oral calcium, magnesium, aluminum, sucralfate, or iron supplements will decrease concentrations of dolutegravir. May increase concentration of metformin (dosage adjustment necessary). Will increase concentration of DOFETILIDE. Dosage increases of dolutegravir may be necessary when used with non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Contraindications/Precautions: Contraindicated in patients receiving dofetilide. Do not use during the first trimester of pregnancy. Do not use in patients with severe hepatic impairment. Use may precipitate hepatitis B or C liver toxicity. Patients should be tested for hepatitis before initiating treatment.

Adverse Effects: Rare cases of LIVER TOXICITY and IMMUNE RECONSTITUTION SYNDROME have occurred during use. The most common adverse effects are sleep disturbances, tiredness, and headache.

Patient Consultation:

Do not take antacids or products containing calcium, zinc, or iron at the same time. Can be taken 2 hours before of 6 hours after these products.

Do not take St. John’s Wort with this medication.

If you miss a dose, take it as soon as you remember. If it is closer to the time of your next dose, skip the missed dose and carry on with your normal dosing schedule. Do not double doses.

Call your healthcare provider if you experience any symptoms of liver dysfunction (yellow eyes or skin, dark urine, light color stools, anorexia, stomach pain, or nausea).

This medication does not prevent you from transmitting HIV-1 to other people. Do not share needles, personal items that have blood or body fluids on them, and use a barrier protection (condom) during use.

[pozmagazine]

People Who Have Taken Many HIV Meds Have Worse Health Outcomes

HIV-positive individuals who have cycled through numerous antiretrovirals have poorer immune system function and more health problems.

People living with HIV who are on treatment for the virus and have cycled through numerous antiretrovirals (ARVs), compared with their counterparts who have not taken many such medications, have lower CD4 counts, poorer control of HIV and more diagnoses of other health conditions, the National AIDS Treatment Advocacy Project (NATAP) reports.

Presenting their findings at the International AIDS Conference (AIDS 2020), which was held virtually earlier this month, investigators overseeing the OPERA cohort analyzed differences between a group of people with HIV who were heavily treatment experienced—meaning they had taken many ARVs over time—compared with those on HIV treatment who were not.

[fundacionluchandovenceras]

TIVICAY DOLUTEGRAVIR Inhibidor de la integrasa . . . . . #tivicay #dolutegravir #inhibidor #integrasa #sodico #arv #retrovirrales #antiretrovirrales #salud #saludresponsable #saludybienestar #medicinas #medicinainterna #medicamentos #medicos #medicines #concienciasocial #fundacionluchandovenceras https://www.instagram.com/p/CBt2cdxneee/?igshid=n5qe4fr4wyxq

[so-so-gay]

Getting the meds ready for a 26 hour journey. I added #Hydroxyzine to my #Tivicay #Descovy and #Zoloft to put me to sleep for the first 15 hour flight. Wake refreshed, then it's another 11 hours after that till I get to #Tokyo. Could I have taken the longer way around the world!? #HongKong #Japan